About Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: ABUS
- CUSIP: N/A
- Previous Close: $3.15
- 50 Day Moving Average: $2.730
- 200 Day Moving Average: $2.953
- 52-Week Range: $2.35 - $5.48
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.85
- P/E Growth: 0.000
- Market Cap: $174.12M
- Outstanding Shares: 54,841,000
- Beta: 1.24
- Net Margins: -1,192.92%
- Return on Equity: -8.50%
- Return on Assets: -6.68%
- Current Ratio: 18.09%
- Quick Ratio: 18.09%
Companies Related to Arbutus Biopharma Corp:
Earnings History for Arbutus Biopharma Corp (NASDAQ:ABUS)Earnings History by Quarter for Arbutus Biopharma Corp (NASDAQ:ABUS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/2/2017|| || || || || || || || |
|11/6/2014||Q314||($0.31)||($0.39)||$3.71 million||$4.40 million||View||N/A|
|8/13/2014||Q214||($0.26)||($0.28)||$3.72 million||$1.80 million||View||N/A|
Earnings Estimates for Arbutus Biopharma Corp (NASDAQ:ABUS)
Current Year EPS Consensus Estimate: $-3.68 EPS
Next Year EPS Consensus Estimate: $-1.70 EPS
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Arbutus Biopharma Corp (NASDAQ:ABUS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Arbutus Biopharma Corp (NASDAQ:ABUS)
Insider Ownership Percentage: 9.20%Insider Trades by Quarter for Arbutus Biopharma Corp (NASDAQ:ABUS)
Institutional Ownership Percentage: 61.24%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/24/2015||Richard C Henriques Jr||Director||Buy||1,000||$6.95||$6,950.00|| |
Headline Trends for Arbutus Biopharma Corp (NASDAQ:ABUS)
Latest Headlines for Arbutus Biopharma Corp (NASDAQ:ABUS)
Frequently Asked Questions for Arbutus Biopharma Corp (NASDAQ:ABUS)
What is Arbutus Biopharma Corp's stock symbol?
Arbutus Biopharma Corp trades on the NASDAQ under the ticker symbol "ABUS."
How were Arbutus Biopharma Corp's earnings last quarter?
Arbutus Biopharma Corp (NASDAQ:ABUS) released its quarterly earnings results on Wednesday, May, 4th. The company reported ($0.19) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.39) by $0.20. Arbutus Biopharma Corp had a negative net margin of 1,192.92% and a negative return on equity of 8.50%.
When will Arbutus Biopharma Corp make its next earnings announcement?
Arbutus Biopharma Corp is scheduled to release their next quarterly earnings announcement on Tuesday, May, 2nd 2017.
Where is Arbutus Biopharma Corp's stock going? Where will Arbutus Biopharma Corp's stock price be in 2017?
6 analysts have issued twelve-month price targets for Arbutus Biopharma Corp's stock. Their forecasts range from $3.00 to $10.00. On average, they expect Arbutus Biopharma Corp's share price to reach $6.25 in the next year.
What are analysts saying about Arbutus Biopharma Corp stock?
Here are some recent quotes from research analysts about Arbutus Biopharma Corp stock:
- 1. Wedbush analysts commented, "We believe ABUS remains undervalued ahead of key clinical readouts in 2017 for its HBV pipeline candidates, a mid:17 readout of Alnylam's Ph 3 patisiran study in ATTR that could lead to a significant royalties to ABUS, and the potential for additional partnerships around its attractive LNP platform." (3/22/2017)
- 2. According to Zacks Investment Research, "Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. " (2/17/2017)
Who owns Arbutus Biopharma Corp stock?
Arbutus Biopharma Corp's stock is owned by many different of institutional and retail investors. Top institutional investors include Ladenburg Thalmann Financial Services Inc. (9.66%), Armistice Capital LLC (3.54%), Falcon Edge Capital LP (3.02%) and Oxford Asset Management (0.29%).
Who sold Arbutus Biopharma Corp stock? Who is selling Arbutus Biopharma Corp stock?
Arbutus Biopharma Corp's stock was sold by a variety of institutional investors in the last quarter, including Falcon Edge Capital LP.
Who bought Arbutus Biopharma Corp stock? Who is buying Arbutus Biopharma Corp stock?
Arbutus Biopharma Corp's stock was bought by a variety of institutional investors in the last quarter, including Ladenburg Thalmann Financial Services Inc., Armistice Capital LLC and Oxford Asset Management.
How do I buy Arbutus Biopharma Corp stock?
Shares of Arbutus Biopharma Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Arbutus Biopharma Corp stock cost?
One share of Arbutus Biopharma Corp stock can currently be purchased for approximately $3.15.
Arbutus Biopharma Corp (ABUS) Chart for Thursday, March, 23, 2017